185 related articles for article (PubMed ID: 20554567)
1. A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients.
Hsu DI; Nguyen M; Nguyen L; Law A; Wong-Beringer A
J Antimicrob Chemother; 2010 Aug; 65(8):1765-70. PubMed ID: 20554567
[TBL] [Abstract][Full Text] [Related]
2. Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database.
Colombo AL; Ngai AL; Bourque M; Bradshaw SK; Strohmaier KM; Taylor AF; Lupinacci RJ; Kartsonis NA
Antimicrob Agents Chemother; 2010 May; 54(5):1864-71. PubMed ID: 20231388
[TBL] [Abstract][Full Text] [Related]
3. Caspofungin therapy of neonates with invasive candidiasis.
Odio CM; Araya R; Pinto LE; Castro CE; Vasquez S; Alfaro B; Sàenz A; Herrera ML; Walsh TJ
Pediatr Infect Dis J; 2004 Dec; 23(12):1093-7. PubMed ID: 15626944
[TBL] [Abstract][Full Text] [Related]
4. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance.
Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2006 Mar; 44(3):760-3. PubMed ID: 16517851
[TBL] [Abstract][Full Text] [Related]
5. Caspofungin for invasive candidiasis at a tertiary care medical center.
Zaas AK; Dodds Ashley ES; Alexander BD; Johnson MD; Perfect JR
Am J Med; 2006 Nov; 119(11):993.e1-6. PubMed ID: 17071169
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of an infant infected with refractory C. parapsilosis with caspofungin.
Ozkaya-Parlakay A; Tezer H; Kazmacan T; Gulhan B; Unal S
J Trop Pediatr; 2014 Aug; 60(4):329-30. PubMed ID: 24567311
[TBL] [Abstract][Full Text] [Related]
7. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis.
Colombo AL; Perfect J; DiNubile M; Bartizal K; Motyl M; Hicks P; Lupinacci R; Sable C; Kartsonis N
Eur J Clin Microbiol Infect Dis; 2003 Aug; 22(8):470-4. PubMed ID: 12884068
[TBL] [Abstract][Full Text] [Related]
8. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.
Cornely OA; Vazquez J; De Waele J; Betts R; Rotstein C; Nucci M; Pappas PG; Ullmann AJ
Mycoses; 2014 Feb; 57(2):79-89. PubMed ID: 23786573
[TBL] [Abstract][Full Text] [Related]
10. Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida krusei.
Shorr AF; Wu C; Kothari S
J Antimicrob Chemother; 2011 Feb; 66(2):375-80. PubMed ID: 21147825
[TBL] [Abstract][Full Text] [Related]
11. Caspofungin for the treatment of less common forms of invasive candidiasis.
Cornely OA; Lasso M; Betts R; Klimko N; Vazquez J; Dobb G; Velez J; Williams-Diaz A; Lipka J; Taylor A; Sable C; Kartsonis N
J Antimicrob Chemother; 2007 Aug; 60(2):363-9. PubMed ID: 17526917
[TBL] [Abstract][Full Text] [Related]
12. Monotherapy with caspofungin for candidaemia in adult patients with cancer: a retrospective, single institution study.
Sipsas NV; Lewis RE; Raad II; Kontoyiannis DP
Int J Antimicrob Agents; 2009 Jul; 34(1):95-8. PubMed ID: 19251404
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.
Montagna MT; Lovero G; Coretti C; Martinelli D; De Giglio O; Iatta R; Balbino S; Rosato A; Caggiano G
BMC Microbiol; 2015 May; 15():106. PubMed ID: 25990252
[TBL] [Abstract][Full Text] [Related]
14. Efungumab and caspofungin: pre-clinical data supporting synergy.
Hodgetts S; Nooney L; Al-Akeel R; Curry A; Awad S; Matthews R; Burnie J
J Antimicrob Chemother; 2008 May; 61(5):1132-9. PubMed ID: 18299636
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials.
Kullberg BJ; Vasquez J; Mootsikapun P; Nucci M; Paiva JA; Garbino J; Yan JL; Aram J; Capparella MR; Conte U; Schlamm H; Swanson R; Herbrecht R
J Antimicrob Chemother; 2017 Aug; 72(8):2368-2377. PubMed ID: 28459966
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of caspofungin in invasive candidiasis and candidemia--de-escalation strategy.
Lichtenstern C; Nguyen TH; Schemmer P; Hoppe-Tichy T; Weigand MA
Mycoses; 2008; 51 Suppl 1():35-46. PubMed ID: 18471160
[TBL] [Abstract][Full Text] [Related]
17. Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial.
DiNubile MJ; Lupinacci RJ; Strohmaier KM; Sable CA; Kartsonis NA
J Crit Care; 2007 Sep; 22(3):237-44. PubMed ID: 17869975
[TBL] [Abstract][Full Text] [Related]
18. Invasive candidiasis in cancer patients: observations from a randomized clinical trial.
DiNubile MJ; Hille D; Sable CA; Kartsonis NA
J Infect; 2005 Jun; 50(5):443-9. PubMed ID: 15907554
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of single large doses of caspofungin in a neutropenic murine model against the "psilosis" group.
Berényi R; Kovács R; Domán M; Gesztelyi R; Kardos G; Juhász B; Perlin D; Majoros L
New Microbiol; 2014 Jul; 37(3):355-62. PubMed ID: 25180850
[TBL] [Abstract][Full Text] [Related]
20. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.
Pappas PG; Rotstein CM; Betts RF; Nucci M; Talwar D; De Waele JJ; Vazquez JA; Dupont BF; Horn DL; Ostrosky-Zeichner L; Reboli AC; Suh B; Digumarti R; Wu C; Kovanda LL; Arnold LJ; Buell DN
Clin Infect Dis; 2007 Oct; 45(7):883-93. PubMed ID: 17806055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]